Aberrant transforming growth factor-beta(TGF-B) pathway in the tumor microenvironment has been highlighted as one of the core resistance pathways of immunotherapy, by excluding tumor-infiltrating lymphocytes (TIL) out of the tumor area. However, no studies have coupled immune phenotypes classified by spatial analysis of TIL in whole slide images (WSI) with TGF-B pathway analysis on a large-scale database. Here, we hypothesized that the immune-excluded phenotype classified by a deep-learning spatial analysis model, Lunit SCOPE IO, would be correlated with the aberrant TGF-B pathway in The Cancer Genome Atlas (TCGA) cohorts. Aberrant TGF-B pathway was measured by Trimmed Mean of M-values (TMM) normalized and transformed to log2 of counts-per-million of previously published gene sets of fibroblast-specific TGF-beta responsive gene signature, using edgeR packages from TCGA RNA-sequencing data (n=6,709) across the 23 cancer types. Lunit SCOPE IO was developed to identify immune phenotypes trained and validated from 3,166 multi-cancer H&E WSI with sections of 2.8e+9 mm2 tumor tissue containing 5.9e+6 TIL annotated by 52 board-certified pathologists. Lunit SCOPE IO classified immune phenotypes as immune-inflamed and -excluded according to the proportion of TIL density either highly conserved in cancer epithelium (CE) or cancer stroma (CS), respectively, and otherwise, classified as immune-desert with low TIL density in CE and CS. Aberrant TGF-B expression was highly enriched in multiple cancer types including pancreatic cancer, head and neck cancer, kidney clear cell carcinoma, lung squamous cell carcinoma, and breast cancer, in ascending order. TGF-B expression was increased in microsatellite-stable tumor samples (p = 7.4e-15) or samples with low tumor mutational burden (TMB, < 10/megabase, p = 4.9e-8), compared to those with microsatellite instability-high or high TMB, respectively. Interestingly, TGF-B expression was highly correlated with the proportion of cancer stroma in WSI (R = 0.315, p < 2.2e-16) and the proportion of immune-excluded phenotype (R = 0.115, p < 2.2e-16) across multiple cancer types. Tumor samples with SMAD4 mutations (n = 161, 2.4%) had significantly higher TGF-B expression (p = 0.0190), and a higher proportion of immune-excluded phenotype (p < 2.2e-16) in WSI, compared to wild-type SMAD4. Aberrant TGF-B pathway is clearly associated with increased proportion of cancer stroma, and excluded TIL, or immune-excluded phenotype in a large-scale pan-carcinoma analysis.
Gahee Park, Sanghoon Song, Hyung-Gyo Cho, Soo Ick Cho, Wonkyung Jung,Sergio Pereira, Donggeun Yoo, Kyunghyun Paeng, Chan-Young Ock.
Lunit, Seoul, Korea, Republic of
Abstract: Deep learning-based predictive biomarker for adjuvant chemotherapy in early-stage hormone receptor-positive breast cancer
Abstract: Pan-cancer analysis of tumor microenvironment using deep learning-based cancer stroma and immune profiling in H&E images
Abstract: Deep learning-based predictive biomarker for immune checkpoint inhibitor response in metastatic non-small cell lung cancer
Abstract: Comprehensive deep learning analysis of H&E tissue phenomics reveals distinct immune landscape and transcriptomic enrichment profile among immune inflamed, excluded and desert subtypes...
Abstract: Deep-learning analysis of H&E images to define three immune phenotypes to reveal loss-of-target in excluded immune cells as a novel resistance mechanism of immune checkpoint inhibitor...
Abstract: Deep learning-based immune phenotype analysis reveals distinct resistance pattern of immune checkpoint inhibitor in non-small cell lung cancer
Reducing Domain Gap by Reducing Style Bias
Predicting breast tumor proliferation from whole-slide images: The TUPAC16 challenge
Accuracy and efficiency of an artificial intelligence tool when counting breast mitoses
Abstract: Artificial intelligence-powered spatial analysis of tumor infiltrating lymphocytes (TIL) to reflect target gene expressions of novel immuno-oncology agents.
Abstract: Distinct subset of immune cells assessed by multiplex immunohistochemistry correlates with immune phenotype classified by ...
Abstract : Pathologic validation of artificial intelligence-powered prediction of combined positive score of PD-L1 immunohistochemistry in urothelial carcinoma.
Abstract : Clinical performance of artificial intelligence-powered annotation of tumor cell PD-L1 expression for treatment of immune-checkpoint inhibitor (ICI) ...
Abstract : Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes predicts survival after immune checkpoint inhibitor therapy across multiple cancer types.
Abstract : Deep learning based radiomic biomarker for predicting the presence of high-grade histologic patterns in lung adenocarcinoma
Abstract : Artificial intelligence-powered tissue analysis reveals distinct tumor-infiltrating lymphocyte profile as a potential biomarker of molecular subtypes in endometrial cancer
Abstract : Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes reveals distinct genomic profile of immune excluded phenotype in pan-carcinoma
Deep learning from HE slides predicts the clinical benefit from adjuvant chemotherapy in hormone receptor-positive breast cancer patients
Abstract : Interim results of phase I dose escalation study of YBL-006: A novel anti-PD-1 monoclonal antibody in advanced solid tumors
Abstract : Assistance with an artificial intelligence-powered PD-L1 analyzer reduces interobserver variation in pathologic reading of tumor proportion score in non-small cell lung cancer
Abstract : AI-powered whole-slide image analysis of tumor-infiltrating lymphocytes for prediction of prognosis in colorectal cancer
Deep Learning Analysis of CT Images Reveals High-Grade Pathological Features to Predict Survival in Lung Adenocarcinoma
Artificial Intelligence–Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non–Small-Cell Lung Cancer
Artificial Intelligence–Powered Hematoxylin and Eosin Analyzer Reveals Distinct Immunologic and Mutational Profiles among Immune Phenotypes in Non–Small-Cell Lung Cancer
Abstract : Artificial Intelligence-Powered Analyzer Reduces Inter-observer Variation in PD-L1 Tumor Proportion Score of Non-Small Cell Lung Cancer
Abstract : Artificial Intelligence-Powered Tumor Purity Assessment From H&E Whole Slide Images Correlates...
Abstract : Deep learning-based H&E analyzer reveals distinct immune profiles and clinical outcomes among immune phenotypes in uterine corpus endometrial carcinoma
Observer Performance Study to Examine the Feasibility of the AI-powered PD-L1 Analyzer to Assist Pathologists’ Assessment of PD-L1 Expression Using Tumor Proportion Score in Non-Small Cell Lung Cancer
Artificial intelligence-powered human epidermal growth factor receptor 2 (HER2) analyzer in breast cancer as an assistance tool for pathologists to reduce interobserver variation
Artificial intelligence-powered whole-slide image analyzer reveals a distinctive distribution of tumor-infiltrating lymphocytes in neuroendocrine tumors and carcinomas
Artificial Intelligence (AI) - powered spatial analysis of tumor-infiltrating lymphocytes (TIL) for prediction of response to neoadjuvant chemotherapy (NAC) in triple negative breast cancer (TNBC)
Artificial intelligence (AI)-powered pathology image analysis merged with spatial transcriptomics reveals distinct TIGIT expression in the immune-excluded tumor-infiltrating lymphocytes
Trastuzumab plus FOLFOX for Gemcitabine/Cisplatin refractory HER2-positive biliary tract cancer: a multi-institutional phase II trial of the Korean Cancer Study Group (KCSG-HB19-14)
The Inflamed Immune Phenotype (IIP): a clinically actionable artificial intelligence (AI)-based biomarker predictive of immune checkpoint inhibitor (ICI) outcomes across >16 primary tumor types
Safety and efficacy of YBL-006, an anti-PD-1 monoclonal antibody in advanced solid tumors: a phase I study
Robust artificial intelligence-powered imaging biomarker based on mammography for risk prediction of breast cancer.